Suchergebnisse - "Gupta, Neeraj"

PubPharm (18)

1

Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach

enthalten in: CPT: pharmacometrics & systems pharmacology | 2024

von Hanley, M. | Yeo, K. | Tugnait, M. | +5

2

Mobocertinib : Mechanism of action, clinical, and translational science

enthalten in: Clinical and translational science | 2024

von Hanley, M. | Camidge, D. | Fram, R. | +1

3

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Zhou, X. | Vaishampayan, U. | Mahalingam, D. | +7

4

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer

enthalten in: British journal of clinical pharmacology | 2022

von Gupta, N. | Hanley, M. | Sinha, V.

CommentOn: Br J Clin Pharmacol. 2022 Feb;88(4):1930-1934. - PMID 34545619

5

Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors

enthalten in: Clinical pharmacology in drug development | 2022

von Zhou, X. | Diderichsen, P. | Gupta, N.

6

Population pharmacokinetic and exposure-response analyses from ALTA-1L : Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC

enthalten in: Clinical and translational science | 2022

von Gupta, N. | Reckamp, K. | Camidge, D. | +8

7

Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

enthalten in: Journal of clinical pharmacology | 2022

von Zhou, X. | Ouerdani, A. | Diderichsen, P. | +1

8

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

enthalten in: Targeted oncology | 2022

von Shimizu, T. | Kuboki, Y. | Lin, C. | +7

ErratumIn: Target Oncol. 2022 Apr 12;:. - PMID 35412171

9

Effect of severe renal impairment on the pharmacokinetics of brigatinib

enthalten in: Investigational new drugs | 2021

von Gupta, N. | Hanley, M. | Kerstein, D. | +4

10

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +4